Related Experiment Video

Updated: Jun 30, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

19.8K

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

Hongge Liang1, Yan Xu1, Jing Zhao1

  • 1Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Cancer Gene Therapy
|March 19, 2024
PubMed

Insights

The Hippo pathway, involving YAP and TAZ, is key to non-small cell lung cancer (NSCLC) drug resistance. Understanding this pathway offers new therapeutic targets for overcoming treatment resistance in NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
  • Targeted therapy and immunotherapy have improved NSCLC patient survival but face challenges with drug resistance.
  • The Hippo pathway is increasingly recognized for its role in NSCLC progression and therapeutic resistance.

Purpose of the Study:

  • To provide a comprehensive overview of the Hippo pathway's involvement in NSCLC.
  • To elucidate the mechanisms by which the Hippo pathway contributes to drug resistance in NSCLC.
  • To identify potential therapeutic targets and biomarkers within the Hippo pathway for NSCLC treatment.

Main Methods:

  • Literature review of studies on the Hippo pathway in NSCLC.
  • Analysis of research detailing drug resistance mechanisms in NSCLC.
  • Synthesis of information on YAP, TAZ, and TEAD interactions in cancer.

Main Results:

  • The Hippo pathway, regulated by YAP and TAZ, significantly influences NSCLC development and treatment outcomes.
  • Dysregulation of the Hippo pathway is a critical factor in the emergence of resistance to NSCLC therapies.
  • Specific components of the Hippo pathway present viable targets for novel anti-cancer drug development.

Conclusions:

  • The Hippo pathway is a critical regulator in NSCLC, particularly in the context of drug resistance.
  • Targeting the Hippo pathway, including YAP/TAZ-TEAD interactions, holds promise for overcoming therapeutic resistance in NSCLC.
  • Further research into Hippo pathway biomarkers could lead to improved patient stratification and treatment strategies for NSCLC.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K